疾病自然疗法

分享&收藏

静脉曲张自然疗法

直立行走给人体腿部的静脉出了个大难题,因为它们缺少动脉血管所具有的强健肌肉层,但是又必须持续地使大量的血液克服重力向上流回心脏。这主要得归功于静脉瓣膜,它们像阀门一样能够防止液体向下回流。尽管如此,随着时间的推移,瓣膜的功能可能会降低,于是血液慢慢积聚在腿部的深静脉里,导致静脉壁的扩张及内皮的损伤。这种状态被称之为静脉机能不全 (Venous insufficiency),其典型的症状是腿部沉重、肿胀、微痛及疲劳感。

静脉瓣膜
(左:正常静脉瓣膜; 右:受损的静脉瓣膜)

静脉曲张 (Varicose veins) 与静脉机能不全密切相关,它是指靠近皮肤表面的静脉受损,即表面可见静脉扩张和扭曲,这有碍美观。静脉曲张在女性中的发病率是男性的2到3倍。站立时间较长的职业会增加静脉机能不全的发生率。怀孕或是肥胖时腹压增加,导致血液向上回流更加困难,也会导致静脉曲张。静脉机能不全的常规治疗方法主要包括减肥、抬高下肢和穿弹力袜。受损后变得难看的静脉可通过注射治疗来去除或经手术切除。

静脉曲张

一些自然疗法在治疗静脉机能不全和静脉曲张方面有一定的有效性。这些治疗方法有很大的相似之处,它们都是通过加强静脉和其它血管的管壁,最终减少液体的渗出。研究表明采用这些疗法可以减轻下肢的肿胀和疼痛,但还没有证据表明有哪一种自然疗法可以治愈那些已经存在的难看的曲张静脉,或是预防新的曲张静脉出现。

警告:一些更危险的疾病 (譬如静脉炎或是血栓形成) 也会出现类似静脉曲张的症状。因此,在使用下面介绍的自然疗法进行自我治疗前最好先找医生做一下诊断。

  • 马栗树 (Horse chestnut): 它是治疗静脉机能不全最常用的草药。总共有800多人参加了有关马栗树治疗静脉机能不全的多项双盲研究。其中最大的一项试验是采用交叉给药的方式随访212名病人达40多天。在这项研究中,研究人员起初给予参与者马栗树或是安慰剂 (作为对照用),20天后在他们不知情的情况下,交叉换用另外一种治疗。研究结果显示,马栗树可以显著地减轻下肢的水肿、疼痛及沉重感。在另外一项比较马栗树及弹力袜疗效的研究中,马栗树治疗也得到了较好的试验结果:使用弹力袜可以较快地减轻水肿,但是12周后两种方法疗效相等,且均优于安慰剂组。目前马栗树的活性成分已经鉴定,它们被统称为马栗树皮素 (Aescin)。马栗树皮素可以减少受压血管壁的液体渗出。
  • 马栗树

参考文献
  1. Neiss A, Bohm C. Demonstration of the effectiveness of the horse-chestnut-seed extract in the varicose syndrome complex [translated from German]. MMW Munch Med Wochenschr. 1976;118:213-216.
  2. Lohr E, Garanin G, Jesau P, et al. Anti-edemic therapy in chronic venous insufficiency with tendency to formation of edema [translated from German]. Munch Med Wochenschr. 1986;128:579-581.
  3. Diehm C, Trampisch HJ, Lange S, et al. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet. 1996;347:292-294.
  4. Kreysel HW, Nissen HP, Enghofer E. A possible role of lysosomal enzymes in the pathogenesis of varicosis and the reduction in their serum activity by Venostasin. Vasa. 1983;12:377-382.
  5. Bougelet C, Roland IH, Ninane N, et al. Effect of aescine on hypoxia-induced neutrophil adherence to umbilical vein endothelium. Eur J Pharmacol. 1998;345:89-95.
  6. Unkauf M, Rehn D, Klinger J, et al. Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittelforschung. 1996;46:478-482.
  7. MacLennan WJ, Wilson J, Rattenhuber V, et al. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology. 1994;40:45-52.
  8. Rehn D, Brunnauer H, Diebschlag W, et al. Investigation of the therapeutic equivalence of different galenical preparations of O-(beta-hydroxyethyl)-rutosides following multiple dose peroral administration. Arzneimittelforschung. 1996;46:488-492.
  9. Rehn D, Unkauf M, Klein P, et al. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency. Arzneimittelforschung. 1996;46:483-487.
  10. Balmer A, Limoni C. Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients [in German; English abstract]. Vasa. 1980;9:76-82.
  11. Bergqvist D, Hallbook, Lindblad B, et al. A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency. Vasa. 1981;10:253-260.
  12. Anderson JH, Geraghty JG, Wilson YT, et al. Paroven and graduated compression hosiery for superficial venous insufficiency. Phlebology. 1990;5:271-276.
  13. van Cauwenberge H. Double blind study of the efficacy of O(beta-hydroxyethyl)-rutosides in the treatment of venous conditions [in French]. Med Hyg (Geneve). 1978;36:4175-4177.
  14. de Jongste AB, Jonker JJ, Huisman MV, et al. A double blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thromb Haemost. 1989;62:826-829.
  15. Prerovsky I, Roztocil K, Hlavova A, et al. The effect of hydroxyethylrutosides after acute and chronic oral adminstration in patients with venous diseases. A double-blind study. Angiologica. 1972;9:408-414.
  16. Cappelli R, Pecchi S, Oberhauser V, et al. Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function. Int J Clin Pharmacol Res. 1987;7:291-299.
  17. Ihme N, Kiesewetter H, Jung F, et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial. Eur J Clin Pharmacol. 1996;50:443-447.
  18. Koscielny J, Radtke H, Hoffmann KH, et al. Fagorutin buckwheat herb tea in chronic venous insufficiency [translated from German]. Z Phytother. 1996;17:147-150,153-156,159.
  19. Tsouderos Y. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Z Kardiol. 1991;80(suppl 7):95-101.
  20. Amato C. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin. Angiology. 1994;45:531-536.
  21. Cospite M, Dominici A. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol. 1989;8(suppl 4):61-65.
  22. Dominguez C, Brautigam I, Gonzalez E, et al. Therapeutic effect of hidrosmin on chronic venous insufficiency if lower limbs. Curr Med Res Opin. 1992;12:623-630.
  23. Fermoso J, Legido AG, del Pino J, et al. Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Curr Ther Res. 1992;52:124-134.
  24. Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology. 1994;45:579-584.
  25. Schwitters B, Masquelier J. OPC in Practice: Bioflavanols and Their Applications. Rome, Italy: Alfa Omega; 1993.
  26. Masquelier J, Dumon MC, Dumas J. Stabilization of collagen by procyanidolic oligomers [in French; English abstract]. Acta Ther. 1981;7:101-105.
  27. Masquelier J. Procyanidolic oligomers (Leucocyanidins) [translated from French]. Parfums Cosmetiques Aromes. 1990;95:89-97.
  28. Tixier JM, Godeau G, Robert AM, et al. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Pharmacol. 1984;33:3933-3939.
  29. Bombardelli E, Morazzoni P. Vitis vinifera L. Fitoterapia. 1995;66:291-317.
  30. Henriet JP. Exemplary study for a phlebotropic substance, the EIVE Study [translated from French]. Fairfield, CT: Primary Source; not dated.
  31. Delacroix P. Double-blind study of Endotelon® in chronic venous insufficiency [translated from French]. La Revue de Medecine. 1981;22:1793-1802.
  32. Thebaut JF, Thebaut P, Vin F. Study of Endotelon® in functional manifestations of peripheral venous insufficiency [translated from French]. Gaz Med. 1985;92:96-100.
  33. Arcangeli P. Pycnogenol in chronic venous insufficiency. Fitoterapia. 2000;71:236-244.
  34. Petrassi C, Mastromarino A, Spartera C. Pycnogenol in chronic venous insufficiency. Phytomedicine. 2000;7:383-388.
  35. Arcangeli P. Pycnogenol in chronic venous insufficiency. Fitoterapia. 2000;71:236-244.
  36. Cesarone MR, Laurora G, DeSactis MT, et al. The microcirculatory activity of Centella asiatica in venous insufficiency: a double-blind study [translated from Italian]. Minerva Cardioangiol. 1994;42:299-304.
  37. Pointel JP, Boccalon H, Cloarec M, et al. Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology. 1987;38:46-50.
  38. Cesarone MR, Laurora G, DeSactis MT, et al. Activity of Centella asiatica in venous insufficiency [in Italian; English abstract]. Minerva Cardioangiol. 1992;40:137-143.
  39. Kiesewetter H, Koscielny J, Kalus U, et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). Arzneimittelforschung. 2000;50:109-117.
  40. Lucker P, Jost V, Wolna P, et al. Efficacy and safety of ruscus extract compared to placebo in patients suffering from chronic venous insufficiency [abstract]. Phytomedicine. 2000;7(suppl 2):P-155.
  41. Laurent R, Gilly R, Frileux C. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. Int Angiol. 1988;7:39-43.
  42. Danielsson G, Jungbeck C, Peterson K, et al. A randomised, controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 2002;23:73-76.
  43. Vanscheidt W, Jost V, Wolna P, et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittelforschung. 2002;52:243-250.
  44. Koch R. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. Phytother Res. 2002;16(suppl 1):S1-5.
  45. Petruzzellis V, Troccoli T, Candiani C, et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency—a double-blind, randomized, controlled study. Angiology. 2002;53:257-263.
  46. Incandela L, Belcaro G, Renton S, et al. HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther. 2002;7(suppl 1):S7-S10.

最后修改日期 : 2009-02-19

© 2017 以上资料由医博士(DrMed)编辑。版权归医博士(DrMed) 和
新世纪医学公司(New Century Medicine,Inc.)所有,未经书面许可,不得转载!